Atlas Venture Stocks List Ranked for 2024 | NYSE,

Symbol	Grade	Name	% Change
LPTX	B	LEAP THERAPEUTICS, INC.	-3.65
BTAI	F	BioXcel Therapeutics, Inc.	-3.69
APVO	F	Aptevo Therapeutics Inc.	-0.38

Related Industries: Biotechnology

Symbol	Grade	Name	Weight
BTEC	D	Principal Healthcare Innovators Index ETF	0.05
IWC	C	iShares Microcap ETF	0.02
UWM	C	ProShares Ultra Russell2000	0.0
VTWO	C	Vanguard Russell 2000 ETF	0.0
SCHB	B	Schwab U.S. Broad Market ETF	0.0

Compare ETFs

Compare IWC to SCHB Compare IWC to VTWO Compare UWM to VTWO

Date	Stock	Title
Apr 25	BTAI	BioXcel Therapeutics to Report First Quarter 2024 Financial Results on May 9, 2024
Apr 24	BTAI	BioXcel Therapeutics Announces Late-Breaking Abstract on Preliminary Findings from Phase 2 Investigator-Sponsored Trial of BXCL701 and KEYTRUDA® in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) Selected for Presentation at 2024 ASCO Annual Meeting
Apr 22	BTAI	BioXcel Therapeutics Announces Plan for Evaluating BXCL501 in the At-Home Setting to Expand Its Market Potential

Related Industries: Biotechnology

Atlas Venture: This article is about the life sciences venture capital firm Atlas Venture, which previously also invested in technology. For the technology team formerly at Atlas Venture, see Accomplice.Atlas Venture is an early-stage venture capital firm that invests in life sciences startup companies in the U.S.. Atlas is headquartered in Cambridge, Massachusetts where the majority of its investments are located.
Atlas rolled out its eleventh biotech fund totaling $350 million in June 2017, after closing its tenth fund in April 2015 with $280 million in commitments. The team is led by five investment partners: Kevin Bitterman, Bruce Booth, Jean-Francois Formela, David Grayzel, and Jason Rhodes.